Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

A total of 542 patients had received prior HT, predominantly LHRH agonists (53.7 %); of these, 455 had received prior LHRH analogue therapy (LHRH agonists or GnRH antagonists). Baseline PSA (media ...

Early prostate cancer usually causes no symptoms, but can include blood in the urine or semen. The outlook is often excellent, especially if doctors diagnose it in the early stages. Prostate ...

“Prostate cancer feeds on testosterone,” explains ... ADT includes medications that affect the production of LHRH: LHRH agonists and LHRH antagonists. 2. LHRH agonists and LHRH antagonists ...

Researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer compared with use of DPP-4i. HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use ...

With parenteral delivery, this risk seems to be equivalent to that associated with orchiectomy, LHRH agonists ... supported by the National Cancer Research Network Prostate Cancer UK studies ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to ...

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

But the fact remains that prostate cancer is the biggest cancer diagnosed among men in the UK - and now, in England generally. Prostate cancer is now the most common type of tumour in England ...

Prostate cancer has become England's most common cancer as more men are getting checked. Prostate Cancer UK analysis shows diagnoses of the disease overtook breast cancer in 2022 and 2023.

There are self-care strategies that may aid in helping to prevent prostate cancer, the second most common cause of cancer-related death in men. Located below the bladder, the prostate is the gland ...

Glucagon-like peptide 1 receptor agonist use was not associated with an increased risk for thyroid cancer compared with use of dipeptidyl peptidase-4 inhibitors. HealthDay News — Glucagon-like peptide ...